Skip to main content
. 2022 Jun 21;128(16):3067–3079. doi: 10.1002/cncr.34348

FIGURE 2.

FIGURE 2

Kaplan–Meier survival estimates for OS according to the NLR. (A) Atezolizumab cohort including oncogene‐addicted patients: NLR low (17.1 months; 95% CI, 15.2–20.0 months; 198 events) versus NLR high (7.8 months; 95% CI, 6.6–9.6 months; 217 events) (p < .0001; HR, 1.88; 95% CI, 1.55–2.28). (B) Docetaxel cohort including oncogene‐addicted patients: NLR low (12.5 months; 95% CI, 10.8–13.8 months; 189 events) versus NLR high (7.8 months; 95% CI, 6.8–9.1 months; 242 events) (p < .0001; HR, 1.49; 95% CI, 1.23–1.81). (C) Atezolizumab cohort excluding EGFR/ALK‐positive patients: NLR low (17.1 months; 95% CI, 15.1–20.0 months; 178 events) versus NLR high (7.6 months; 95% CI, 6.2–9.6 months; 199 events) (p < .0001; HR, 1.93; 95% CI, 1.57–2.37). (D) Docetaxel cohort excluding EGFR/ALK‐positive patients: NLR low (11.3 months; 95% CI, 9.7–13.3 months; 175 events) versus NLR high (7.7 months; 95% CI, 6.8–8.9 months; 230 events) (p = .0011; HR, 1.38; 95% CI, 1.13–1.69). ALKindicates anaplastic lymphoma kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio; OS, overall survival